Apalutamide, Enzalutamide May Improve Prostate Cancer Outcomes
In separate studies, apalutamide, an investigational agent, and enzalutamide prolonged metastasis-free survival in men with non-metastatic castration-resistant prostate cancer.
Genitourinary (GU) Cancers Symposium
Cabozantinib Superior to Sunitinib for First-Line RCC Treatment Across all Subgroups
Findings from the phase 2 CABOSUN study showed that, compared with sunitinib, cabozantinib improves PFS and the ORR among patients with advanced RCC.
Adjuvant Docetaxel May Worsen Outcomes vs Surveillance in Prostate Cancer
It was previously unknown whether chemotherapy or surveillance leads to improved outcomes in prostate cancer post-prostatectomy.
Cabozantinib May Improve Survival in mCRPC Patient Subgroup
COMET-1 and COMET-2 previously showed no overall survival benefit with cabozantinib.
Ramucirumab Plus Docetaxel May Improve QoL in Urothelial Carcinoma
The impact of this treatment on quality of life was not previously reported.
Adjuvant Sunitinib Increases Mortality Risk Among Older Women With Renal Cell Cancer
Previous findings suggested that there were no benefits to overall survival or disease-free survival with VEGF-TKIs vs placebo.
5-FU/Cisplatin, Gemcitabine May Be Effective Options for Invasive Bladder Cancer
This study was designed to evaluate the efficacy of each treatment using 3-year distant metastasis-free survival as a primary outcome.
Antibiotics May Indirectly Improve PFS Among Patients With RCC Receiving TKIs
Patients receiving VEGF-TKIs are likely to have treatment dose reductions, delays, or interruptions because of diarrhea, which occurs in about 50% of cases.
Papillary Renal Cell Carcinomas May Respond to Crizotinib
Patients with PRCC1 frequently show MET mutations. Crizotinib, a dual inhibitor of MET and ALK, has shown promising activity in MET-altered cancers.
Nivolumab Monotherapy May Yield 8% Complete Response Rate in Urothelial Carcinoma
Seventy-eight patients with metastatic urothelial carcinoma received intravenous nivolumab until disease progression or discontinuation.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Genitourinary Cancers Symposium 2018
Loading... 
Loading...